Jessica Lowney

Statistics

Publications

Citations

166

H-Index

Active since

2019

Affiliations

Dana-Farber Cancer Institute(Current)

Beth Israel Deaconess Medical Center

Harvard University

Jessica Lowney is an author at Dana-Farber Cancer Institute specializing in chronic lymphocytic leukemia therapy, immunotherapy, and cancer immunotherapy.

Publications per year

2019–2021

Publications

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · The Lancet Oncology · 2021 · 102 citations

Medicine, Hematology, Pharmacology +11

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie et al. · Blood · 2019 · 31 citations

Medicine, Hematology, Pharmacology +10

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · Blood · 2020 · 19 citations

Medicine, Hematology, Pharmacology +11

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Jennifer L. Crombie, Svitlana Tyekucheva, Zixu Wang et al. · Blood · 2020 · 14 citations

Pharmacy, Pharmacotherapy, Restorative Treatment Planning +5

1–4 of 4